Mergers & Acquisitions - Mergers & Acquisitions, Generics, Research


Impax in deal with Perrigo; Cipla eyes South Africa acquisition


Impax Laboratories (Nasdaq: IPXL) said yesterday that it plans to collaborate with fellow US drugmaker…

CiplaCipla MedproGenericsImpax LaboratoriesMarkets & MarketingMergers & AcquisitionsNorth AmericaPerrigoResearchRest of the World

Sanofi buys Colombian drugmaker; Presents encouraging eliglustat and Lyxumia data; Revizes deal with B-MS


In what turns out to be a very busy couple of days for French drug major Sanofi (Euronext: SAN), the…

AvaproBiotechnologyBristol-Myers SquibbCardio-vascularDiabeteseliglustatGenericsGenfar SAGlobalLyxumiaMarkets & MarketingMergers & AcquisitionsPharmaceuticalPlavixRare diseasesResearchSanofiSouth America

News briefs: Roche's dalcetrapib; Coherus/Daiichi deal; Mercury Pharma; AEterna Zentaris


Swiss drug major Roche (ROG: SIX) saw its shares drop 4.5% to 159.30 Swiss francs by around midday yesterday,…

AEterna ZentarisBiotechnologyCoherus BioSciencesDaiichi SankyodalcetrapibGenericsKeryx BiopharmaceuticalsLicensingMercury PharmaMergers & AcquisitionsperifosinePharmaceuticalResearchRoche

Kyowa Hakko sets up biosimilars joint venture with Fujifilm


Japanese digital camera and medical equipment conglomerate Fujifilm and drugmaker Kyowa Hakko Kirin have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyFujifilm Kyowa Kirin BiologicsGenericsHumiraKyowa Hakko KirinMergers & AcquisitionsResearch

Teva ups stake in CureTech to 75% following positive clinical results in lymphoma


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an…

CureTechGenericsMergers & AcquisitionsOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Back to top